Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model [0.03%]
通过调整抗VEGF/细胞毒药物/抗PD-1联合治疗的时间表来克服肺癌模型中的免疫抵抗性
Guillaume Sicard,Dorian Protzenko,Sarah Giacometti et al.
Guillaume Sicard et al.
Background: Many tumors are refractory to immune checkpoint inhibitors, but their combination with cytotoxics is expected to improve sensitivity. Understanding how and when cytotoxics best re-stimulate tumor immunity could help overcome res...
Leveraging genomics, transcriptomics and epigenomics to understand chemoimmunotherapy resistance in chronic lymphocytic leukemia [0.03%]
利用基因组学、转录组学和表观遗传学来理解慢性淋巴细胞白血病中的化疗免疫疗法抗性问题
Shin Yeu Ong,Lili Wang
Shin Yeu Ong
Patients with chronic lymphocytic leukemia (CLL) have differing clinical outcomes. Recent advances integrating multi-omic data have uncovered molecular subtypes in CLL with different prognostic implications and may allow better prediction o...
Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors [0.03%]
卵巢癌化疗耐药性发展的新型参与者：卵巢癌干细胞，非编码RNA和核受体
Shahil Alam,Pankaj Kumar Giri
Shahil Alam
Ovarian cancer (OC) ranks as the fifth leading factor for female mortality globally, with a substantial burden of new cases and mortality recorded annually. Survival rates vary significantly based on the stage of diagnosis, with advanced st...
Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia [0.03%]
活性氧及其在急性髓系白血病的发病机制和抗药性中的作用
Jamshid Sorouri Khorashad,Sian Rizzo,Alex Tonks
Jamshid Sorouri Khorashad
Relapse following a short clinical response to therapy is the major challenge for the management of acute myeloid leukemia (AML) patients. Leukemic stem cells (LSC), as the source of relapse, have been investigated for their metabolic prefe...
Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications [0.03%]
半乳糖凝集素-1通过调控Nrf2/Keap1信号通路影响癌症药物抗性的细胞和分子机制研究
İlhan Yaylim,Melek Aru,Ammad Ahmad Farooqi et al.
İlhan Yaylim et al.
Oxidative stress is characterized by the deregulation of the redox state in the cells, which plays a role in the initiation of various types of cancers. The activity of galectin-1 (Gal-1) depends on the cell redox state and the redox state ...
Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progression [0.03%]
肿瘤来源的胞外囊泡介导的血管内皮细胞获得耐药性与癌症进展
Masahiro Morimoto,Nako Maishi,Kyoko Hida
Masahiro Morimoto
Angiogenesis by endothelial cells (ECs) is essential for tumor growth. Angiogenesis inhibitors are used in combination with anticancer drugs in many tumor types, but tumors eventually become resistant. Previously, the underlying mechanism f...
Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel [0.03%]
利托那韦逆转前列腺癌细胞对多西他赛和卡巴他赛的获得性耐药性
Eric van der Putten,Katja Wosikowski,Jos H Beijnen et al.
Eric van der Putten et al.
Aim: Docetaxel is a microtubule-stabilizing drug used for the treatment of several cancers, including prostate cancer. Resistance to docetaxel can either occur through intrinsic resistance or develop under therapeutic pressure, i.e., acquir...
Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers [0.03%]
免疫治疗抵抗性癌症中的调节性T细胞(Treg)靶点研究
Pavlina Spiliopoulou,Paramjit Kaur,Tracey Hammett et al.
Pavlina Spiliopoulou et al.
Primary or secondary (i.e., acquired) resistance is a common occurrence in cancer patients and is often associated with high numbers of T regulatory (Treg) cells (CD4+CD25+FOXP3+). The approval of ipilimumab and the development of similar p...
Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer [0.03%]
胰腺癌中与化疗耐药性、侵袭能力和癌症干细相关的节点：糖原合酶激酶3β
Masahiro Uehara,Takahiro Domoto,Satoshi Takenaka et al.
Masahiro Uehara et al.
The treatment of pancreatic cancer remains a significant clinical challenge due to the limited number of patients eligible for curative (R0) surgery, failures in the clinical development of targeted and immune therapies, and the pervasive a...
Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies [0.03%]
乳腺癌中的免疫检查点抑制剂：发展，耐药机制及潜在管理策略
Rachel Sj Wong,Rebecca Jm Ong,Joline Sj Lim
Rachel Sj Wong
The use of immune checkpoint inhibitors (ICIs) has increased exponentially in the past decade, although its progress specifically for breast cancer has been modest. The first U.S. Food and Drug Administration approval for ICI in breast canc...